Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease

N‐Acetylcysteine alleviates gut dysbiosis and glucose metabolic disorder in high‐fat diet‐fed mice

“…In contrast, the abundance of Allobaculum is usually decreased in HFD‐fed mice, and evidence suggests that Allobaculum is the main contributor to reducing glucose digestion of the host . In addition, Desulfovibrio is considered to be positively correlated with obesity and chronic low‐grade inflammation, whereas Blautia is responsible for the occurrence of non‐alcoholic fatty liver disease . These reports are consistent with the findings of the present study that NAC increases the Akkermansia , Bifidobacterium , Lactobacillus , and Allobaculum populations, but suppresses the growth of Desulfovibrio and Blautia .…”

Sugary Kefir Strain Lactobacillus mali APS1 Ameliorated Hepatic Steatosis by Regulation of SIRT‐1/Nrf‐2 and Gut Microbiota in Rats

“…The role of genus Prevotella in NAFLD is still controversial in human study. Several previous studies indicated that the abundance of Prevotella was reduced in the patients with NAFLD, but the reversed findings were observed by other group . The differences in environmental conditions and dietary intake might be also the crucial factors affecting the abundance of Prevotella …”

“…Liver inflammation is also frequently associated with increased production of endotoxins and lipopolysaccharides from Gram‐negative bacteria, such as Escherichia and Shigella genera . Shen et al . indicated that, in contrast to the health subjects, the abundance of family Lachnospiraceae, Enterobacteriaceae, Erysipelotrichaceae, Streptococcaceae, and the abundance of genus Escherichia, Shigella , and Blautia were enriched in the NAFLD patients.…”

Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function

“…In NAFL, comparison groups included healthy controls 9,8,10,11,15,16,18,23 and obese controls 21 . In NASH, comparison groups included healthy controls 9,10,12,13,18,19 , obese controls 7 , and NAFL 24,16 . In NAFLD-associated advanced fibrosis, comparison groups included healthy controls 20 and NAFLD without advanced fibrosis (stage<2) 17,24,22,16 .…”

“…In NASH, comparison groups included healthy controls 9,10,12,13,18,19 , obese controls 7 , and NAFL 24,16 . In NAFLD-associated advanced fibrosis, comparison groups included healthy controls 20 and NAFLD without advanced fibrosis (stage<2) 17,24,22,16 . In NAFLD-related HCC, the comparison group included NAFLD-related cirrhosis without HCC 20 .…”